Erectile Dysfunction (ED) Clinical Trials

Find Erectile Dysfunction (ED) Clinical Trials Near You

Quantitative and Qualitative Study of Anxiety in Patients Under Active Surveillance for Localized Prostate Cancer and Their Partners.

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Prostate cancer (PCa) is the most common cancer and the third leading cause of cancer-related death among men in France. Active surveillance is one of the management options for low-risk prostate cancer. Its aim is to delay or avoid radical treatment, such as surgery or radiotherapy, which can cause side effects including urinary incontinence, erectile dysfunction, or radiation-induced cystitis. Active surveillance involves regular monitoring of potential tumor progression through serum PSA testing, MRI scans, and prostate biopsies. Few studies have investigated the psychological adjustment of patients undergoing active surveillance for prostate cancer, and even fewer have explored the relationship between the patients' anxiety symptoms and those of their partners. To our knowledge, no study has yet quantitatively or qualitatively assessed the anxiety of both patients and their partners. It appears essential to better characterize the anxiety symptoms in these individuals in order to offer them appropriate psychological support.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• Age ≥ 18 years.

• Patients who started active surveillance for localized prostate cancer from 2007 to 2023 and are followed in the Urology Department of Lille University Hospital.

• Affiliation to a social security scheme.

• Obtaining patient consent.

• Having a life partner or an unidentified partner recognized as the person sharing the patient's daily life

Locations
Other Locations
France
CHU de Lille
RECRUITING
Lille
Contact Information
Primary
Jonathan OLIVIER, Dr
jonathan.olivier@chu-lille.fr
0320444398
Time Frame
Start Date: 2025-03-23
Estimated Completion Date: 2027-03-23
Participants
Target number of participants: 432
Sponsors
Collaborators: Ligue contre le cancer, France
Leads: University Hospital, Lille

This content was sourced from clinicaltrials.gov